The Latest Breaking News from Pfizer

The government isn’t doing much to prevent shortages of the only drug that treats syphilis during pregnancy

There are other reasons to consider buying a dividend stock besides the high yield. Here's a closer look at two stocks that offer yields over 5% right now.

Any pharmaceutical has risk of side effects, but a COVID infection is far more dangerous than the vaccines

Results confirm how uncommon known complications are as researchers confirm benefits from vaccines still ‘vastly outweigh the risks’

The pharmaceutical industry is expected to witness robust growth over the coming years due to growing healthcare needs and advancements in technology. Given this positive backdrop, let’s analyze the upside potential of pharma stocks Pfizer (PFE) and Johnson & Johnson (JNJ).

Pfizer stock is trading at price levels last seen in 2016. The 2025 forecast for PFE stock looks positive, though, and it should go up over the medium to long term.

Read about Pfizer's settlement in the Lipitor antitrust lawsuit, where they have agreed to pay million to resolve the case. Stay informed with our late...

This vivid account of the Hungarian biochemist who endured decades of derision before pioneering Pfizer’s Covid vaccine is a tribute to her tenacity and self-belief

Pfizer (PFE) is facing hurdles due to weakened demand for its products and pipeline diversification challenges. Nevertheless, the company exhibits long-term potential through strategic acquisitions. Given this scenario, what course of action should be considered ahead of the upcoming earnings release? Read more to find out.